PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pharmacist Inhaler Review Cuts Readmissions in COPD, Not Overall

pharmacist-led interventioninhaler therapyCOPDasthmahospital readmissionemergency departmenttransitions of careLABALAMAinhaled corticosteroidrandomized controlled trialmedication accessCMS Hospital Readmission Reduction Program Pulmonology / Respiratory

Background Information

Pharmacist intervention cuts COPD readmissions effectively.

Chronic obstructive pulmonary disease (COPD) significantly contributes to hospital readmissions, which are costly and often preventable. The pharmacist-led intervention reduced the risk of 30-day and 6-month readmissions or emergency department visits for COPD patients, with a hazard ratio of 0.63 and 0.42, respectively. While overall results weren't significant, the intervention notably benefited COPD patients, highlighting the pharmacist's role in optimizing inhaler therapy. Pharmacist interventions can reduce COPD-related readmissions by optimizing inhaler therapy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Parrott TD, Wallace MD, Eble SH, Niehoff KM, Gao Y, Choi L, Prigmore HL, Dear ML, Rice TW, Sevin CM, Choma NN, Zuckerman AD

Citation: Parrott TD, Wallace MD, Eble SH, et al. A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmission (PILLAR): A Randomized Controlled Trial. CHEST pulmonary. 2026;4(2):100231. doi:10.1016/j.chpulm.2025.100231

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.